Patent Application
20250186425
PPARgamma (PPARG) is a type II ligand-dependent nuclear hormone receptor (belonging to the PPAR nuclear receptor subfamily) that functions as an obligate heterodimer with retinoid X receptors (RXRs). PPARG is predominantly expressed in adipose tissue, colon, macrophages and the luminal layers of the urothelium. PPARG is known as a master regulator of adipogenesis, functioning to regulate adipocyte differentiation, fatty acid storage and glucose metabolism. PPARG has also been shown to play an important role in the metabolism and inflammation of macrophages, where it is induced by IL4 and controls glutamine metabolism. In the normal urothelium, PPARG is critical for its homeostasis and regeneration.
The role for PPARG in cancer was originally inferred from genomic studies that identified a PAX8-PPARG chromosomal rearrangement in follicular thyroid carcinomas. More recently, PPARG has been found to be over-expressed and genetically altered in the luminal subtype of urothelial cancer. This is consistent with reports that long-term use of PPARG agonists is associated with an increased incidence of urothelial cancer. Most urothelial cancers are urothelial carcinoma, which are classified as either non-muscle-invasive urothelial cancer (NMIUC, 70%), muscle-invasive urothelial cancer (MIUC, 25%) or metastatic urothelial cancer (MUC, 5%). MIUC is usually diagnosed de novo but may arise from the 10 to 20% of NMIUC cases that eventually progress. MIUC is a heterogeneous and aggressive disease, associated with a five-year survival rate of 60% for patients with localized disease and less than 10% for patients with distant metastases. Molecular understanding of NMIUC and MIUC has improved significantly, including the association between molecular subtypes and urothelial differentiation. Several molecular classes of MIUC have been proposed, whereby an activated PPARG signature features prominently in the luminal subtypes. First-line treatment is chemotherapy with several options in chemo-ineligible or second line, but treatment options are limited with poor overall survival rates.
The need exists to develop effective PPARG modulators for treating cancers such as NMIUC, MIUC, and MUC, and related conditions.
Provided herein are compounds having the Formula I:
and pharmaceutically acceptable salts and compositions thereof, wherein R1, R2, R3, R5, R6, R7, W, X, Y, Z, q and r are as described herein. In one aspect, the disclosed compounds of Formula I and pharmaceutically acceptable salts thereof modulate PPARG (e.g., as agonists such as inverse agonists, and are useful in a variety of therapeutic applications such as, for example, in treating cancer. As such, their uses for treating diseases responsive to the inhibition of PPARG are included.
Pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts of the disclosed compounds of Formula I, as well as methods for their preparation are also included.
In a first embodiment, provided herein is a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
When used in connection to describe a chemical group that may have multiple points of attachment, a hyphen (-) designates the point of attachment of that group to the variable to which it is defined. For example, —NRDC(O)ORG and —NRDC(S)OR mean that the point of attachment for this group occurs on the nitrogen atom.
The terms “halo” and “halogen” refer to an atom selected from fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), and iodine (iodo, —I).
The term “alkyl” when used alone or as part of a larger moiety, such as “haloalkyl”, and the like, means saturated straight-chain or branched monovalent hydrocarbon radical.
“Alkoxy” means an alkyl radical attached through an oxygen linking atom, represented by —O-alkyl. For example, “(C1-C4)alkoxy” includes methoxy, ethoxy, proproxy, and butoxy.
The term “haloalkyl” includes mono, poly, and perhaloalkyl groups where the halogens are independently selected from fluorine, chlorine, bromine, and iodine.
“Haloalkoxy” is a haloalkyl group which is attached to another moiety via an oxygen atom such as, e.g., —OCHF2 or —OCF3.
The term oxo means the group ═O.
The term “heteroaryl” used alone or as part of a larger moiety refers to a 5- to 12-membered aromatic radical containing 1-4 heteroatoms selected from N, O, and S. A heteroaryl group may be mono- or bi-cyclic. Monocyclic heteroaryl includes, for example, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, triazinyl, tetrazinyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, etc. Bi-cyclic heteroaryls include groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings. Nonlimiting examples include indolyl, imidazopyridinyl, benzooxazolyl, benzooxodiazolyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, quinazolinyl, quinoxalinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrazolopyridinyl, thienopyridinyl, thienopyrimidinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. It will be understood that when specified, optional substituents on a heteroaryl group may be present on any substitutable position and, include, e.g., the position at which the heteroaryl is attached.
The term “heterocyclyl” means a 5- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S. It can be monocyclic, bicyclic (e.g., a bridged, fused, or spiro bicyclic ring), or tricyclic. A heterocyclyl ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, terahydropyranyl, pyrrolidinyl, pyridinonyl, pyrrolidonyl, piperidinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, morpholinyl, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, oxctanyl, azetidinyl and tetrahydropyrimidinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclyl” also includes, e.g., unsaturated heterocyclic radicals fused to another unsaturated heterocyclic radical or aryl or heteroaryl ring, such as for example, tetrahydronaphthyridine, indolinone, dihydropyrrolotriazole, imidazopyrimidine, quinolinone, dioxaspirodecane. It will also be understood that when specified, optional substituents on a heterocyclyl group may be present on any substitutable position and include, e.g., the position at which the heterocyclyl is attached (e.g., in the case of an optionally substituted heterocyclyl or heterocyclyl which is optionally substituted).
The term “spiro” refers to two rings that shares one ring atom (e.g., carbon).
The term “fused” refers to two rings that share two adjacent ring atoms with one another.
The term “bridged” refers to two rings that share three ring atoms with one another.
The disclosed compounds may exist in one or more tautomeric forms, such as those below, and are included herein.
The terms “subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like). Typically, the subject is a human in need of treatment.
The term “inhibit,” “inhibition” or “inhibiting” includes a decrease in the baseline activity of a biological activity or process.
As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some aspects, treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment. In other aspects, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of exposure to a particular organism, or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to delay their recurrence.
The term “pharmaceutically acceptable carrier” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
For use in medicines, the salts of the compounds described herein refer to non-toxic “pharmaceutically acceptable salts.” Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts. Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include e.g., salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, nitric, and sulfuric acids) and of organic acids (such as, acetic acid, benzenesulfonic, benzoic, methanesulfonic, and p-toluenesulfonic acids). Compounds of the present teachings with acidic groups such as carboxylic acids can form pharmaceutically acceptable salts with pharmaceutically acceptable base(s). Suitable pharmaceutically acceptable basic salts include e.g., ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts). Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, benzoates and salts with amino acids such as glutamic acid.
The term “effective amount” or “therapeutically effective amount” refers to an amount of a compound described herein that will elicit a desired or beneficial biological or medical response of a subject e.g., a dosage of between 0.01-100 mg/kg body weight/day.
In a second embodiment, R′ in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is hydrogen, wherein the remaining variables are as described above for Formula I.
In a third embodiment, X, Y, and Z in the compound of Formula I, or a pharmaceutically acceptable salt thereof, are each —CR4, wherein the remaining variables are as described above for Formula I or the second embodiment.
In a fourth embodiment, R4 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, and (C1-C4)alkoxy, wherein the remaining variables are as described above for Formula I or the second or third embodiment. Alternatively, as part of a fourth embodiment, R4 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is hydrogen, wherein the remaining variables are as described above for Formula I or the second or third embodiment.
In a fifth embodiment, R3 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is cyano, wherein the remaining variables are as described above for Formula I or the second, third, or fourth embodiment.
In a sixth embodiment, R2 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from halo, —SRa, —SORa, —SO2Ra, and —SO(═NRa)Rb, wherein the remaining variables are as described above for Formula I or the second, third, fourth, or fifth embodiment. Alternatively, as part of a sixth embodiment, R2 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is-SO2Ra, wherein the remaining variables are as described above for Formula I or the second, third, fourth, or fifth embodiment. In another alternative, as part of a sixth embodiment, R2 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from chloro and —SO2Me, wherein the remaining variables are as described above for Formula I or the second, third, fourth, or fifth embodiment.
In a seventh embodiment, R6 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from halo, oxo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —(C1-C4)alkylORd, —(C1-C4)alkylC(O)ORd, —NRaRe, —(C1-C4)alkylNRdRe, —C(O)NRaRe, —(C1-C4)alkylC(O)NRaRe, —C(O)Rd, —C(O)ORd, —S(O)2Rd, —S(O)Rd, and —SRd, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, or sixth embodiment.
In an eighth embodiment, r in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is 0, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, or seventh embodiment.
In a ninth embodiment, q in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is 1, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, or eighth embodiment.
In a tenth embodiment, R7 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from halo, oxo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —(C1-C4)alkylORd, —(C1-C4)alkylC(O)ORd, —NRaRe, —(C1-C4)alkylNRdRe, —C(O)NRaRe, —(C1-C4)alkylC(O)NRdRe, —C(O)Rd, —C(O)OR4, —S(O)2Rd, —S(O)Rd, and —SRd, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment. Alternatively, as part of a tenth embodiment, R7 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is halo, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment. In another alternative, as part of a tenth embodiment, R7 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is fluoro, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
In an eleventh embodiment, W in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from O and CH2, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment. Alternatively, as part of an eleventh embodiment, W in the compound of Formula I, or a pharmaceutically acceptable salt thereof. is O, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment.
In a twelfth embodiment, R5 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from phenyl and monocyclic heteroaryl, each of which are optionally substituted with 1 to 3 groups selected from R8, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment. Alternatively, as part of a twelfth embodiment, R5 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from phenyl and pyrazolyl, each of which are optionally substituted with 1 to 3 groups selected from R8, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment.
In a thirteenth embodiment, R8 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from halo, oxo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —(C1-C4)alkylORd, —(C1-C4)alkylC(O)ORd, —NRaRe, —(C1-C4)alkylNRdRe, —C(O)NRaRe, —(C1-C4)alkylC(O)NRdRe, —C(O)Rd.—C(O)ORd, —S(O)2Rd, —S(O)Rd, and —SRd, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment. Alternatively, as part of a thirteenth embodiment, R8 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from halo and (C1-C4)alkyl, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment. In another alternative, as part of a thirteenth embodiment, R8 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from halo and (C1-C4)alkyl, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment. In another alternative, as part of a thirteenth embodiment, R8 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is selected from chloro and methyl, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment.
Compounds having the Formula I are further disclosed in the Exemplification and are included in the present disclosure. Pharmaceutically acceptable salts thereof as well as the neutral forms are included.
The compounds and compositions described herein are generally useful for modulating the activity of PPARG. In some aspects, the compounds, pharmaceutical acceptable salts, and pharmaceutical compositions described herein inhibit the activity PPARG. In some aspects, the compounds and pharmaceutical acceptable salts disclosed herein are agonists of PPARG. In some aspects, the compounds and pharmaceutical acceptable salts disclosed herein are agonists of PPARG. In some aspects, the compounds and pharmaceutical acceptable salts disclosed herein are inverse agonists of PPARG. In one aspect, “inverse-agonists” refer to agents that bind to the same receptor binding site as a agonist (e.g., the binding site of a nuclear receptor such as PPARG) and not only antagonizes the effects of an agonist but, moreover, exerts the opposite effect by suppressing spontaneous receptor signaling (when present).
In some aspects, the compounds and pharmaceutical acceptable salts disclosed herein overcome the activated state of PPARG function resulting from alteration in PPARG activity (mutation, amplification or overexpression) or from RXRA activating mutations. In some aspect, the compounds and pharmaceutical acceptable salts disclosed herein increase the repressive state (NCOR1 recruitment) to a higher degree than previously disclosed PPARG modulators such as prior inverse agonists. Such results even arise in the mutant context. See e.g., the table qualitatively assessing NCOR1 recruitment and repression of PPARG target genes in HT1197 in the Exemplification section.
In some aspects, the compounds and pharmaceutical compositions described herein are useful in treating a disorder associated with PPARG function. Thus, provided herein are methods of treating a disorder associated with PPARG function, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof.
Also provided is the use of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disorder associated with PPARG function. Also provided is a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof, for use in treating a disorder associated with PPARG.
In one aspect, the disorder associated with PPARG is cancer. In some aspects, the cancer is associated with an up-regulated peroxisome proliferator-activated receptor (PPAR) signaling pathway. In some aspects, the up-regulated PPAR signaling pathway is associated with increased expression of one or more genes selected from Uroplakin 1A (UPK1A), Uroplakin IB(UPK1B), Uroplakin (UPK2), Keratin 20 (KRT20), GATA Binding Protein 3 (GAT A3), Nuclear Receptor Corepressor 1 (NCOR1), Nuclear Receptor Corepressor 2 (NCOR2), Fatty Acid Binding Protein 4 (FABP4), Forkhead Box Al(FOXA1), CD36 Molecule (CD36), Acyl-CoA Oxidase 1 (ACOX1), 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 (HMGCS2), Acyl-CoA Synthetase Long-Chain Family Member 5 (ACSL5), Arachidonate 5-Lipoxygenase (ALOX5), Acyl-CoA Synthetase Long-Chain Family Member 1 (ACSL1), and Angiopoietin Like 4 (ANGPTL4).
In some aspects, the cancer treated by the compounds, pharmaceutically acceptable salt thereof, and pharmaceutical compositions described herein is selected from breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, renal cancer, bladder cancer, testicular cancer, urothelial cancer (e.g., non-muscle-invasive urothelial cancer, muscle-invasive urothelial cancer, metastatic urothelial cancer), skin cancer, melanoma, colon cancer, kidney cancer, brain cancer and a hematopoietic cancer (e.g., lymphoma, multiple myeloma and leukemia). In one aspect, the cancer treated by the compounds, pharmaceutically acceptable salt thereof, and pharmaceutical compositions described herein is urothelial cancer such as non-muscle-invasive urothelial cancer, muscle-invasive urothelial cancer, and metastatic urothelial cancer.
Other uses besides cancer are contemplated and include e.g., metabolic diseases (e.g., osteoporosis, rachitis, arthrosis, obesity, type I and type II diabetes mellitus), lipid metabolism disorder, pancreatitis, glucose metabolism disorder, diabetic neuropathy, diabetic complications, hyperuricemia, osteoporosis, rachitis, arthrosis inflammatory diseases (e.g., inflammatory skin diseases such as psoriasis, atopic dermatitis, eczema, acne vulgaris, other dermatitides and pruritus), pulmonary disorders (e.g., asthma and chronic obstructive pulmonary disease), autoimmune disease, neurodegenerative disease (e.g., multiple sclerosis, Alzheimer's disease, and Parkinson's disease), cardiovascular diseases (e.g., selected from atherosclerosis, venous and arterial occlusive diseases), restenosis after invasive procedures, cardiomyopathy, myocardial fibrosis, congestive heart failure, angiogenesis and neovascularization in neoplastic diseases and renal diseases.
In certain aspects, a pharmaceutical composition described herein is formulated for administration to a patient in need of such composition. Pharmaceutical compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the pharmaceutical compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
In some aspects, the pharmaceutical compositions are administered orally.
A specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound described herein in the composition will also depend upon the particular compound in the pharmaceutical composition.
The representative examples that follow are intended to help illustrate the present disclosure, and are not intended to, nor should they be construed to, limit the scope of the invention.
1-(2-amino-4-chloro-6-fluorophenyl) ethan-1-one: To a solution of 3-chloro-5-fluoroaniline (20.0 g, 137 mmol, 1.0 equiv.) in p-xylene (40.0 mL) was added BCl3 (182.7 mL, 1 M, 1.33 equiv.) at 0-5° C. over 2 hours, then the mixture was warm up to 22° C. for 0.5 h, was stirred at 20-22° C. for 10 minutes, then acetonitrile (57.8 mL, 1.1 mol, 8.0 equiv.) was added dropwise into the mixture at 25° C. over 20 minutes. The mixture was stirred at 20-22° C. for 10 minutes, then p-xylene (44.8 mL) was added into the mixture. Then AlCl3 (10.3 g, 76.9 mmol, 4.2 mL, 0.56 equiv.) was added to the mixture in one portion. The mixture was stirred at 22° C. for 1 hour, then stirred at 75-77° C. for 12 hour. HCl (4 N, 200 mL) was added and the reaction mixture was stirred at 80° C. for 4 hours. The mixture was poured into water (800 mL) and extracted with ethyl acetate (1.500 L). The organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum. The residue was purified by silica gel column chromatography (50:1 to 20:1 petroleum ether:ethyl acetate) to afford the title compound (4.6 g, 18% yield) as a light yellow solid. LCMS [M+1]=188.0/190.0. 1H NMR (CHLOROFORM-d, 400 MHZ) δ 6.31-6.52 (m, 4H), 2.58 (d, J=8.4 Hz, 3H).
Step 1, methyl 2-chloro-5-cyano-benzoate: To a solution of 2-chloro-5-cyano-benzoic acid (10 g, 55.0 mmol, 1.0 equiv.) was added SOCI2 (82.0 g, 689.2 mmol, 50 mL, 12.5 equiv.). The reaction mixture was stirred at 80° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was dissolved in THF (50 mL) and added to MeOH (50 mL). The residue was diluted with saturated NaHCO3 aqueous solution (100 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the title compound (9 g, 84% yield) as a white solid. 1H NMR (400 MHZ, CDCl3)δ 8.15 (d, J=2.0 Hz, 1H), 7.70 (dd, J=2.0, 8.4 Hz, 1H), 7.60 (d, J=8.4 Hz, 1H), 3.98 (s, 3H).
Step 2, 5-cyano-2-methylsulfanyl-benzoic acid: To a solution of NaSMe (35.83 g, 511 mmol, 2.5 equiv.) in DMF (400 mL) was added dropwise a solution of methyl 2-chloro-5-cyano-benzoate (40 g, 205 mmol, 1.0 equiv.) in DMF (400 mL) at 0° C. Then the mixture was stirred at 0° C. for 3 hours. The pH of the reaction mixture was adjusted to pH=1 with HCl (1M). The mixture was filtered and the filter cake was dried over under vacuum to afford the title compound (30 g, 76% yield) as a white solid. LCMS [M−1]=192.1. 1H NMR (400 MHZ, DMSO-d6) δ 13.53 (br s, 1H), 8.21 (d, J=2.0 Hz, 1H), 7.92 (dd, J=2.0, 8.4 Hz, 1H), 7.51 (d, J=8.6 Hz, 1H), 2.46 (s, 3H).
Step 3, 5-cyano-2-(methylthio)benzoyl chloride: A solution of 5-cyano-2-(methylthio)benzoic acid (4.2 g, 22.0 mmol, 1.0 equiv.) in SOCI2 (56 mL) was stirred at 80° C. for 1 hour. The mixture was concentrated under reduced pressure to afford the title compound (4.6 g, 99% yield) as a yellow solid. The product was used without further purification.
A solution of 2-chloro-5-cyano-benzoic acid (2.5 g, 13.8 mmol) in SOCI2 (25 mL) was stirred at 80° C. for 1 hour. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to afford the title compound (2.8 g, crude) as a yellow solid, the product was used directly in next step.
To a solution of 3,5-difluoroaniline (8.9 g, 68.9 mmol, 1.0 equiv.) in CH3CN (85 mL) was added BCl3 (1 M, 72.4 mL, 1.05 equiv.) at 0° C. Then AlCl3 (10.1 g, 75.8 mmol, 4.1 mL, 1.1 equiv.) was added to the mixture in three portions and the mixture was then stirred at 80° C. for 16 hours. The mixture was cooled to 0° C. and then aqueous HCl (4M, 80 mL) was added and the mixture was stirred at 80° C. for 2 hours. The mixture was cooled to room temperature and extracted with EtOAc (2×150 mL). The combined organic layers were washed with saturated aqueous NaHCO3 solution (2×50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the title compound (8.0 g, 68% yield) as a light-yellow solid. LCMS: calculated for [M+H]+ (C8H7F2NO) requires m/z=172.0, found m/z=172.1. 1H NMR (400 MHZ, CDCl3), δ 6.5 (br s, 2H), 6.0-6.2 (m, 2H), 2.6 (d, J=8.4 Hz, 3H).
To a solution of 1-(2-amino-4,6-difluoro-phenyl) ethanone (2 g, 11.7 mmol, 1.0 equiv.) in THF (20 mL) was added NaH (467 mg, 11.7 mmol, 60% dispersion in oil, 1.0 equiv.) at 0° C. The mixture was stirred for 30 minutes before the dropwise addition of a solution of 2-chloro-5-cyano-benzoyl chloride (2.6 g. 12.8 mmol, 1.1 equiv.) in THF (10 mL). The mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched by the addition saturated aqueous NH4Cl (15 mL) at 15° C., diluted with water (20 mL), and filtered. The filter cake was triturated with EtOAc (20 mL) and filtered to afford the title compound (2.4 g, 61% yield) as a white solid. LCMS: calculated for [M+H]+ (C16H9F3N2O2) requires m/z=335.0, found m/z=335.0. 1H NMR (400 MHZ, DMSO-d6) δ 11.2 (s, 1H), 8.1 (d. J=2.0 Hz, 1H), 8.0 (dd, J=8.4, 2.2 Hz, 1H), 7.8 (d, J=8.4 Hz, 1H), 7.5-7.5 (m, 1H), 7.3 (ddd, J=11.2, 8.8, 2.2 Hz, 1H), 2.5-2.6 (m, 3H).
To a solution of N-(2-acetyl-3,5-difluoro-phenyl)-2-chloro-5-cyanobenzamide (2.5 g. 7.5 mmol, 1.0 equiv.) in dioxane (40 mL) was added NaOH (3.0 g. 74.7 mmol, 10.0 equiv.). The mixture was stirred at 110° C. for 1.5 hours. The pH of the reaction mixture was adjusted to 5 with aqueous HCl (1 M) and then diluted with water (30 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (2×100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a crude residue that was purified by preparative HPLC(column: Welch Xtimate C18 250×70 mm×10 um; mobile phase: 15-45% acetonitrile in water (10 mM NH4HCO3)). This afforded the title compound (570 mg. 24% yield, 98% purity) as a white solid after concentration under reduced pressure. LCMS: calculated for [M+H]+ (C16H7ClF2N2O) requires m/z=317.0, found m/z=317.0. 1H NMR (400 MHZ, DMSO-d6) δ 9.2-10.3 (m, 1H), 8.2 (d, J=2.0 Hz, 1H), 8.0 (dd, J=8.4, 2.0 Hz, 1H), 7.9 (d. J=8.4 Hz, 1H), 7.0-7.2 (m, 2H), 6.1 (s, 1H).
To a mixture of 2-bromo-1,5-difluoro-3-nitro-benzene (20.0 g. 84.0 mmol, 1.0 equiv.) and 4-chlorophenol (10.8 g, 84.0 mmol, 8.2 mL, 1.0 equiv.) in DMA (50 mL) was added Cs2CO3 (30.1 g. 92.4 mmol, 1.1 equiv.) in one portion at RT under N2. The mixture was stirred at 65° C. for 5 minutes. The reaction mixture was poured into ice water (500 mL) and stirred for 10 minutes. The aqueous phase was extracted with MTBE (3×350 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (100% petroleum ether) to afford a mixture of the title compound and 2-bromo-5-(4-chlorophenoxy)-1-fluoro-3-nitro-benzene (15.8 g. 45.6 mmol) as yellow oil. The mixture of regioisomers was carried forward into the next step. 1H NMR (400 MHZ, CHLOROFORM-d)δ 8.01-7.93 (m, 1H), 7.77 (dd. J=2.4, 7.7 Hz, 1H), 7.47 (t, J=1.9 Hz, 1H), 7.43-7.42 (m, 1H), 7.44-7.40 (m, 3H), 7.35-7.27 (m, 2H), 7.08-6.99 (m, 4H), 6.93 (d, J=8.9 Hz, 1H), 6.76 (dd, J=2.8, 9.0 Hz, 1H).
To a solution of a mixture 2-bromo-5-(4-chlorophenoxy)-1-fluoro-3-nitro-benzene and 2-bromo-1-(4-chlorophenoxy)-5-fluoro-3-nitro-benzene (14.8 g, 42.7 mmol, 1.0 equiv.) and iron (0) (11.9 g. 213.5 mmol, 5.0 equiv.) in ethanol (300 mL) was added a solution of NH4Cl (11.4 g, 213.5 mmol, 5.0 equiv.) in water (100 mL) in one portion at RT under N2. The mixture was stirred at 80° C. for 1 hour. The mixture was filtered through a pad of celite and concentrated to ⅓ of the original volume under reduced pressure. The resulting solution was diluted with water (200 mL) and the aqueous phase was extracted with ethyl acetate (2×200 mL). The combined organic layers were washed with brine (2×20 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (50:1 to 8:1 petroleum ether:ethyl acetate) to afford the title compound (7.0 g. 52% yield) as yellow oil and the undesired regioisomer 2-bromo-5-(4-chlorophenoxy)-3-fluoro-aniline (3.3 g. 24% yield) as yellow oil. LCMS [M−1]=314.1/315.9. 1H NMR (400 MHz, CHLOROFORM-d)δ=7.34-7.28 (m, 2H), 6.98-6.91 (m, 2H), 6.29 (dd, J=2.5, 10.0 Hz, 1H), 6.03 (dd, J=1.5, 2.5 Hz, 1H), 3.81 (br s, 2H).
To a mixture of 2-bromo-3-(4-chlorophenoxy)-5-fluoroaniline (1 g, 3.16 mmol, 1.0 equiv.) and tributyl(1-ethoxyvinyl) stannane (586 μL, 1.74 mmol, 0.55 equiv.) in toluene (10 mL) was added Pd(PPh3)4 (365 mg, 316 μmol, 0.1 equiv.) at RT under N2. The mixture was stirred at 120° C. for 4 hours under N2. Then the reaction was cooled to RT and an additional charge of tributyl(1-ethoxyvinyl) stannane (586.4 μL. 1.74 mmol, 0.55 equiv.) was added to the mixture. The mixture was stirred at 120° C. for 12 hours. The reaction mixture was poured into an aqueous solution of.KF (20 mL) and stirred for 2 hours. The aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 3-(4-chlorophenoxy)-2-(1-ethoxyvinyl)-5-fluoroaniline (2.1 g. crude) as brown oil, which was used in next step without further purification.
A solution of 3-(4-chlorophenoxy)-2-(1-ethoxyvinyl)-5-fluoroaniline (970 mg, crude) in acetic acid (18 mL) and water (2 mL) was stirred at RT for 4 hours. The reaction mixture was concentrated under reduced pressure and then treated with a saturated aqueous solution of NaHCO3 (70 mL) at 20° C. The aqueous layer was extracted with ethyl acetate (4×50 mL) and the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10:1 to 5:1 petroleum ether:ethyl acetate) to afford the title compound (530 mg, 60% yield) as a yellow solid. 1H NMR (400 MHZ, CHLOROFORM-d)δ 7.40-7.33 (m, 2H), 7.04-6.99 (m, 2H), 6.52-6.11 (m, 2H), 6.08 (dd, J=2.4, 10.4 Hz, 1H), 5.76 (dd, J=2.4, 10.0 Hz, 1H), 2.59 (s, 3H).
To a solution of 1-(2-amino-6-(4-chlorophenoxy)-4-fluorophenyl) ethan-1-one (200 mg, 715 μmol, 1.0 equiv.) in isopropyl acetate (3 mL) was added 5-cyano-2-methylsulfanyl-benzoyl chloride (151 mg, 715 μmol, 1.0 equiv.). The mixture was stirred at 80° C. for 16 hours. The mixture was filtered and the filter cake was triturated with MTBE at RT for 1 hour to afford the title compound (200 mg, 62% yield) as a white solid. 1H NMR (400 MHZ, CHLOROFORM-d) § 12.04 (s, 1H), 8.35 (dd, J=2.4, 11.1 Hz, 1H), 7.90 (d, J=1.6 Hz, 1H), 7.72 (dd, J=1.8, 8.4 Hz, 1H), 7.45-7.39 (m, 3H), 7.04 (d, J=8.8 Hz, 2H), 6.32 (dd, J=2.4, 9.4 Hz, 1H), 2.69 (s, 3H), 2.54 (s, 3H).
To a solution of N-(2-acetyl-3-(4-chlorophenoxy)-5-fluorophenyl)-5-cyano-2-(methylthio)benzamide (200 mg, 440 μmol, 1.0 equiv.) in 2-MeTHF (5 mL) was added LiOH (11.6 mg, 484 μmol, 1.1 equiv.). The mixture was stirred at 95° C. for 14 hours. The pH of the solution was adjusted pH=1 with aqueoue 1 M HCl. The solid that precipitated from the solution was filtered off and triturated with acetonitrile at RT to afford the title compound (200 mg, crude) as a white solid. 1H NMR (400 MHZ, METHANOL-d4)δ 7.94-7.86 (m, 2H), 7.65 (d, J=8.2 Hz, 1H), 7.45 (d, J=8.8 Hz, 2H), 7.23 (br d, J=8.8 Hz, 1H), 7.11 (d, J=8.6 Hz, 2H), 6.79-6.69 (m, 2H), 2.60 (s, 3H).
To a solution of 3-(5-(4-chlorophenoxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylthio)benzonitrile (110 mg, 252 μmol, 1 equiv.) in acetone (2.8 mL), water (1.6 mL), THF (2 mL) and MeOH (2 mL) was added Oxone (774 mg, 1.26 mmol, 5 equiv.). The reaction mixture was stirred at 40° C. for 1.5 hours. The reaction mixture was quenched by the addition of an aqueous solution of Na2SO3 (800 mg) in water (10 mL) at RT. The aqueous layer was extracted with DCM (2×10 mL) and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC(column: Phenomenex Luna C18 75×30 mm×3 um; mobile phase: 1-50% acetonitrile in water (+formic acid)) to afford the title compound (49.1 mg, 42% yield) as a white solid. LCMS [M+1]=469.0. 1H NMR (400 MHZ, METHANOL-d4)δ 8.37 (d, J=8.0 Hz, 1H), 8.20 (br d, J=8.4 Hz, 1H), 8.13 (s, 1H), 7.41 (d, J=8.8 Hz, 2H), 7.06 (d, J=8.8 Hz, 2H), 7.00 (br d, J=8.4 Hz, 1H), 6.55 (br d, J=9.4 Hz, 1H), 6.32-6.22 (m, 1H), 3.20 (s, 3H).
To a solution of 1-(2-amino-6-(4-chlorophenoxy)-4-fluorophenyl) ethanone (100 mg, 358 μmol, 1.0 equiv.) in isopropyl acetate (2.0 mL) was added 2-chloro-5-cyano-benzoyl chloride (78.6 mg, 393 μmol, 1.1 equiv.). Then the reaction mixture was stirred at 80° C. for 12 hours. The reaction mixture was cooled to RT and concentrated under reduced pressure. The residue was triturated with acetonitrile to afford the title compound (85 mg, 51% yield) as a yellow solid. 1H NMR (400 MHZ, CHLOROFORM-d)δ 11.89-11.79 (m, 1H), 8.33 (dd, J=2.4, 10.8 Hz, 1H), 7.93 (d, J=1.8 Hz, 1H), 7.73-7.71 (dd, J=2.0, 8.0 Hz, 1H), 7.64-7.62 (d, J=8.4 Hz, 1H), 7.44-7.41 (m, 2H), 7.06-7.03 (m, 2H), 6.36-6.33 (dd, J=2.4, 9.4 Hz, 1H), 2.68 (s, 3H).
To a solution of N-(2-acetyl-3-(4-chlorophenoxy)-5-fluorophenyl)-2-chloro-5-cyanobenzamide (80 mg, 181 μmol, 1.0 equiv.) in 2-MeTHF (1.0 mL), was added LiOH (8.64 mg, 361 μmol, 2.0 equiv.). The reaction mixture was stirred at 80° C. for 16 hours under N2. The pH of the reaction mixture was adjusted pH=3 with aqueous 1 M HCl. The precipitate that formed during the pH adjustment was collected by filtration. The crude product was triturated with acetonitrile to afford the title compound (36 mg, 46% yield) as a white solid. LCMS [M+1]=424.9. 1H NMR (400 MHZ, METHANOL-d4)δ 8.07-8.04 (m, 1H), 7.95-7.91 (m, 1H), 7.85-7.81 (m, 1H), 7.42-7.37 (m, 2H), 7.07-7.02 (m, 3H), 6.59-6.54 (m, 1H), 6.21 (br s, 1H).
To a solution of 1-(2-amino-4,6-difluoro-phenyl) ethanone (400 mg. 2.34 mmol, 1.0 equiv.) in isopropyl acetate (10 mL) was added 5-cyano-2-methylsulfanyl-benzoyl chloride (544 mg, 2.57 mmol, 1.1 equiv.). The mixture was stirred at 80° C. for 16 hours. The reaction mixture was concentrated under reduced pressure to afford the title compound (540 mg, 67% yield) as a white solid. 1H NMR (400 MHZ, DMSO-d6) δ 11.19 (s, 1H), 8.03 (m, 1H), 7.96 (m, 1H), 7.58-7.54 (m, 2H), 7.27 (m, 1H), 2.50 (s, 3H), 2.49 (s, 3H).
To a solution of N-(2-acetyl-3,5-difluoro-phenyl)-5-cyano-2-methylsulfanyl-benzamide (100 mg, 288.7 μmol, 1.0 equiv.) in dioxane (2 mL) was added LiOH (6.9 mg, 289 μmol, 1.0 equiv.). The mixture was stirred at 110° C. for 2 hours. The pH of the reaction mixture was adjusted to pH=1 with aqueous 1 M HCl. A precipitate formed during the pH adjustment. The precipitate was filtered off and the filter cake was dried under vacuum to afford the title compound (80 mg, 84% yield) as a yellow solid.
To a solution of 1-methyl-1H-pyrazol-4-ol (300 mg, 3.06 mmol, 1.0 equiv.) in THF (2.0 mL), was added NaH (122 mg. 3.06 mmol, 1.0 equiv.; 60% dispersion in oil). The mixture was stirred at RT for 1 hour. The reaction mixture was concentrated under reduced pressure to afford 1-methylpyrazol-4-yl)oxy sodium (368 mg, crude) as a white solid.
To a solution of 3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylthio)benzonitrile (400 mg, 1.22 mmol, 1.0 equiv.) in DMF (2.0 mL) was added (1-methylpyrazol-4-yl)oxy sodium (365.7 mg. 3.05 mmol, 2.5 equiv.). The reaction mixture was stirred at 100° C. for 16 hours. The pH of the reaction mixture was adjusted to pH=1 with aqueous 1 M HCl. A precipitate formed during the pH adjustment which was filtered off. The residue was purified by preparative HPLC(column: Phenomenex Luna C18 75×30 mm×3 um; mobile phase: 10-40% acetonitrile in water (+formic acid)) to afford the title compound (65.0 mg, 13% yield) as a white solid. 1H NMR (400 MHZ, METHANOL-d4)δ 7.85 (dd, J=1.6, 8.4 Hz, 1H), 7.81 (d, J=1.6 Hz, 1H), 7.67 (s, 1H), 7.59 (d, J=8.4 Hz, 1H), 7.44 (s, 1H), 6.90 (dd, J=1.8, 9.2 Hz, 1H), 6.59 (dd, J=2.2, 10.8 Hz, 1H), 6.25 (br s, 1H), 3.92 (s, 3H), 2.64-2.49 (m, 3H).
To a solution of 3-(7-fluoro-5-((1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylthio)benzonitrile (50 mg, 123 μmol, 1.0 equiv.) in acetone (3.5 mL), water (2.0 mL), MeOH (2.5 mL) and THF (2.5 mL) was added Oxone (378 mg, 615 μmol, 5.0 equiv.) and the reaction mixture solution was stirred at 30° C. for 3.5 hours. The reaction mixture was quenched by the addition of a saturated aqueous solution of Na2SO3 (9 mg) in water (1.0 mL) at 20° C. The aqueous layer was extracted with DCM (2×5 mL) and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was triturated with acetonitrile to afford the title compound (14.3 mg, 26% yield) as a white solid. LCMS [M+1]=439.1. 1H NMR (400 MHZ, METHANOL-d4)δ 8.37 (d, J=8.2 Hz, 1H), 8.20 (dd, J=1.4, 8.2 Hz, 1H), 8.14 (d, J=1.2 Hz, 1H), 7.68 (s, 1H), 7.46 (s, 1H), 6.87 (br d, J=7.0 Hz, 1H), 6.60 (dd, J=1.8, 10.8 Hz, 1H), 6.30 (br s, 1H), 3.92 (s, 3H), 3.24-3.18 (m, 3H).
The title compound was prepared in similar manner to that described for 3-(7-fluoro-5-((1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile (Example 3) using N-(2-acetyl-5-chloro-3-fluorophenyl)-5-cyano-2-(methylthio)benzamide as the starting material. LCMS [M+1]=455.0. 1H NMR (400 MHZ, METHANOL-d4)δ 8.37 (d, J=8.2 Hz, 1H), 8.20 (br d, J=8.2 Hz, 1H), 8.15 (s, 1H), 7.68 (s, 1H), 7.45 (s, 1H), 7.20 (br s, 1H), 6.77 (s, 1H), 6.31 (br s, 1H), 3.93 (s, 3H), 3.21 (br s, 3H).
To a solution of 6-chloropyridin-3-ol (105 mg, 810.5 μmol, 1.0 equiv.) in THF (2 mL) was added NaH (32.4 mg, 811 μmol, 1.0 equiv.; 60% dispersion in oil) at 0° C., then the mixture solution was stirred at 20° C. for 2 hours. The mixture was concentrated under reduced pressure to afford (6-chloro-3-pyridyl)oxy sodium (123 mg, crude) as a white solid.
To a solution of 4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile (100 mg, 235 μmol, 1.0 equiv.) in DMF (1.5 mL) was added (6-chloro-3-pyridyl)oxy sodium (61.4 mg, 474 μmol, 1.0 equiv.). The mixture was stirred at 100° C. for 20 hours. The mixture was quenched with a saturated aqueous NH4Cl solution and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 75×30 mm×3 um; mobile phase: 20-50% acetonitrile in water (+formic acid)) to afford the title compound (16.9 mg, 10% yield) as yellow solid. LCMS [M+1]=426.0. 1H NMR (400 MHZ, DMSO-d6) δ 12.15-12.08 (m, 1H), 8.22 (d, J=1.3 Hz, 1H), 8.10-8.04 (m, 2H), 7.91 (d, J=8.4 Hz, 1H), 7.49-7.39 (m, 1H), 7.37-7.31 (m, 1H), 7.28-7.17 (m, 1H), 7.03 (br d, J=9.7 Hz, 1H), 5.96 (s, 1H).
To a solution of 4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile (500 mg, 1.58 mmol, 1.0 equiv.) in DMF (7 mL) was added (4-chlorophenyl) methanol (270 mg, 1.89 mmol, 1.2 equiv.) and potassium tert-butoxide (532 mg, 4.74 mmol, 3.0 equiv.). The mixture was stirred at 100° C. for 16 hours. The reaction mixture was diluted with water and ethyl acetate. The organic phase was separated, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (5:1 petroleum ether:ethyl acetate). The material was then purified by preparative HPLC(column: Phenomenex Luna C18 75×30 mm×3 um; mobile phase: 45-75% acetonitrile in water (+formic acid)) to afford the title compound (22.0 mg, 3.2% yield) as a white solid. LCMS [M+1]=438.9. 1H NMR (400 MHZ, CHLOROFORM-d)δ 9.96-9.15 (m, 1H), 7.97 (d, J=1.8 Hz, 1H), 7.67-7.63 (m, 1H), 7.63-7.60 (m, 1H), 7.49-7.44 (m, 4H), 7.40 (dd, J=1.8, 10.1 Hz, 1H), 7.04 (s, 1H), 6.79 (dd, J=2.0, 10.0 Hz, 1H), 5.30 (s, 2H).
To a mixture of 2-bromo-4-fluoro-6-nitroaniline (2.0 g, 8.5 mmol, 1.0 equiv.) in H2SO4 (25.8 mL, 50% purity) and H2O (6.5 mL) was added NaNO2 (769 mg, 11.2 mmol, 1.3 equiv.) in portions at 0° C. under N2. The mixture was stirred at 0° C. for 30 minutes before KI (3.7 g, 22.3 mmol, 2.6 equiv.) was added to the mixture and the resulting mixture was stirred at 0° C. for 40 minutes. The reaction mixture was poured into ice-water (200 mL) and stirred for 10 minutes. The aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with saturated aqueous NaHCO3 (200 mL) and brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (100:1 to 20:1 petroleum ether:ethyl acetate) to afford the title compound (2.5 g, 50% yield) as a yellow solid. 1H NMR (400 MHZ, CHLOROFORM-d) δ 7.66 (dd, J=2.8, 7.4 Hz, 1H), 7.36 (dd, J=2.8, 7.3 Hz, 1H).
To a mixture of 1-bromo-5-fluoro-2-iodo-3-nitro-benzene (2.5 g, 6.5 mmol, 90.0% purity, 1.0 equiv.) and NH4Cl (1.74 g, 32.52 mmol, 5.0 equiv.) in ethanol (30 mL) and H2O (10 mL) was added Fe (1.8 g, 32.5 mmol, 5.0 equiv.) in one portion at 20° C. under N2. The mixture was stirred at 80° C. for 2 hours. The mixture was filtered over a pad of celite and the filtrate was concentrated in vacuum. The residue was poured into ice-water (200 mL). The aqueous phase was extracted with ethyl acetate (2×150 mL). The combined organic layers were washed with brine (2×20 mL), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50:1 to 10: petroleum ether:ethyl acetate) to afford the title compound (2.0 g. 97% yield) as light yellow solid. LCMS [M+1]=315.8. 1H NMR (400 MHZ, CHLOROFORM-d)δ 6.84 (dd, J=2.6, 8.2 Hz, 1H), 6.41 (dd, J=2.6, 10.2 Hz, 1H), 4.48 (br s, 2H).
To a mixture of 3-bromo-5-fluoro-2-iodo-aniline (7.0 g, 22.2 mmol, 1.0 equiv.) and tributyl(1-ethoxyvinyl) stannane (8.8 g, 24.4 mmol, 1.1 equiv.) in toluene (100 mL) was added Pd(PPh3)4 (2.6 g. 2.2 mmol, 0.1 equiv.) in one portion at 20° C. under N2. The mixture was stirred at 120° C. for 16 hours under N2. The mixture was cooled to 20° C. and then a solution of aqueous KF (100 mL) was added and the mixture was stirred at 20° C. for 4 hours. The aqueous phase was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine (2×20 mL), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (100:1 to 20:1 petroleum ether:ethyl acetate) to afford the title compound (4.2 g, 73% yield) as a yellow solid. LCMS [M−1]=258.0. 1H NMR (400 MHZ, CHLOROFORM-d)δ 6.71 (dd, J=2.4, 8.3 Hz, 1H), 6.35 (dd, J=2.4, 10.4 Hz, 1H), 4.56 (d, J=2.2 Hz, 1H), 4.29 (d, J=2.2 Hz, 1H), 4.18 (br s, 2H), 3.91 (q. J=7.2 Hz, 2H), 1.38 (t, J=7.0 Hz, 3H).
To a mixture of 3-bromo-2-(1-ethoxyvinyl)-5-fluoro-aniline (4.2 g, 16.2 mmol, 1.0 equiv.) in acetic acid (72 mL) was added H2O (8 mL) in one portion at 20° C. under N2. The mixture was stirred at 20° C. for 10 hours. The mixture was concentrated under reduced pressure and then a saturated aqueous solution of NaHCO3 (200 mL) was added. The aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum. The residue was purified by silica gel column chromatography (99:1 to 20:1 petroleum ether:ethyl acetate) to afford the title compound (1.9 g. 51% yield) as yellow solid. LCMS [M−1]=229.9. 1H NMR (400 MHZ, CHLOROFORM-d)δ 6.71 (dd, J=2.4, 8.2 Hz, 1H), 6.34 (dd, J=2.4, 10.4 Hz, 1H), 4.89 (br s, 2H), 2.66 (s, 3H).
To a mixture of 1-(2-amino-6-bromo-4-fluoro-phenyl) ethanone (1.0 g, 4.3 mmol, 1.0 equiv.), K3PO4 (1.8 g. 8.6 mmol, 2.0 equiv.) and 2-[(4-chlorophenyl)methyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.3 g. 5.2 mmol, 1.2 equiv.) in ethanol (8 mL)/H2O (2 mL) was added [2-(2-aminophenyl)phenyl]-methylsulfonyloxy-palladium; ditert-butyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (342 mg, 431 μmol, 0.1 equiv.) at 20° C. under N2. The mixture was stirred at 80° C. for 16 hours under N2. \The mixture was cooled to 20° C. and filtered through a pad of celite. The filtrate was poured into water (200 mL), and the aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine (25 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50:1 to 20:1 petroleum ether:ethyl acetate) to afford the title compound (274 mg, 23% yield) as yellow oil. LCMS [M+1]=278.0. 1H NMR (400 MHZ, CHLOROFORM-d)δ 7.29-7.24 (m, 2H), 7.05 (d, J=8.4 Hz, 2H), 6.30 (dd, J=2.4, 10.2 Hz, 1H), 6.20 (dd, J=2.4, 9.6 Hz, 1H), 4.59 (br s, 2H), 3.98 (s, 2H), 2.40 (s, 3H).
A mixture of 1-[2-amino-6-[(4-chlorophenyl)methyl]-4-fluoro-phenylJethanone (220 mg, 792 μmol, 1.0 equiv.) and 5-cyano-2-methylsulfanyl-benzoyl chloride (184 mg. 871 μmol, 1.1 equiv.) in isopropyl acetate (1 mL) was stirred at 80° C. for 16 hours. The mixture was cooled to 20° C. and then concentrated under reduced pressure. H2O (10 mL) was the added to the residue and the mixture was stirred at 20° C. for 10 minutes. The precipitate was filtered off with vacuum. The crude product was triturated with acetonitrile at 20° C. for 30 minutes to affored the title compound (260 mg, 73% yield) as white solid. LCMS [M+1]=453.1. 1H NMR (400 MHZ, CHLOROFORM-d)δ 9.29 (s, 1H), 8.02 (dd. J=2.4, 10.4 Hz, 1H), 7.82 (d, J=1.8 Hz, 1H), 7.70 (dd, J=1.8, 8.4 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 7.33-7.28 (m, 2H), 7.05 (d, J=8.4 Hz, 2H), 6.70 (dd, J=2.4, 8.8 Hz, 1H), 4.09 (s, 2H), 2.55 (s. 3H), 2.48 (s, 3H).
To a mixture of N-[2-acetyl-3-[(4-chlorophenyl)methyl]-5-fluoro-phenyl]-5-cyano-2-methylsulfanyl-benzamide (250 mg, 552 μmol, 1.0 equiv.) in dioxane (3 mL) was added LiOH (14.5 mg, 607 μmol, 1.1 equiv.) at 20° C. under N2. The mixture was stirred at 110° C. for 5 hours. The mixture was cooled to 20° C. and then diluted with H2O (20 mL). The pH of the mixture was adjust pH=4-5 with aqueous 1N HCl. The precipitate that formed was filtered off and washed with water. The crude solid was triturated with acetonitrile at for 1 hour to afford the title compound (200 mg, 83% yield) as white solid. LCMS [M+1]=435.1. 1H NMR (400 MHZ, METHANOL-d4)δ 7.83 (dd, J=1.6, 8.4 Hz, 1H), 7.77 (d, J=1.8 Hz, 1H), 7.57 (d, J=8.4 Hz, 1H), 7.27-7.22 (m, 2H), 7.22-7.17 (m, 2H), 7.14 (dd, J=2.6, 9.2 Hz, 1H), 6.92 (dd, J=2.4, 9.8 Hz, 1H), 6.18 (s, 1H), 4.80 (s, 2H), 2.54 (s, 3H).
To a mixture of 3-[5-[(4-chlorophenyl)methyl]-7-fluoro-4-oxo-1H-quinolin-2-yl]-4-methylsulfanyl-benzonitrile (100 mg, 230 μmol, 1.0 equiv.) in acetone (1.4 mL)/H2O (0.8 mL)/THF (1 mL)/MeOH (1 mL) was added Oxone (424 mg, 690 μmol, 3.0 equiv.)RT under N2. The mixture was stirred at 50° C. for 16 hours. The mixture was cooled to RT before the addition of a saturated aqueous solution of Na2SO3 (3 mL). The resulting mixture was stirred at RT for 10 minutes. The aqueous phase was extracted with ethyl acetate (50 mL). The organic layer was washed with brine (5 mL), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 75×30 mm×3 um; mobile phase: [35-65% acetonitrile in water (+formic acid) to afford the title compound (28 mg. 26% yield) as white solid. LCMS [M+1]=467.0. 1H NMR (400 MHZ, METHANOL-d4)δ 8.36 (d, J=8.2 Hz, 1H), 8.19 (dd, J=1.6, 8.2 Hz, 1H), 8.14-8.08 (m, 1H), 7.28-7.23 (m, 2H), 7.23-7.17 (m, 2H), 7.09 (dd, J=2.4, 9.2 Hz, 1H), 6.92 (dd, J=2.0, 9.6 Hz, 1H), 6.21 (s, 1H), 4.81 (s, 2H), 3.17 (s, 3H).
Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylated NCOR1 ID2 peptide (Biotin-GHSFADPASNLGLEDIIRKALMG-amide) to PPARG/RXRA LBD heterodimer. Specifically, a 20 microliters of TR-FRET master mix consisting of 2 nM WT PPARG LBD (e. coli expressed, His-TEV-Q203-Y477; Uniprot ID P37231-2), 2 nM WT RXRA LBD or mutant S427F RXRA LBD (e. coli expressed, Flag-TEV-E228-T462; P19793-1), 50 nM NCOR1, 80 nM Rosiglitazone, 25 nM streptavidin-d2 (Cisbio) and 0.3 nM Anti-His Tb(Cisbio) in 25 mM MOPS pH 7.4, 25 mM KCl, 1 mM EDTA, 0.01% BSA, 0.01% Tween-20 and 1 mM TCEP was added to 384-well plates containing duplicate 10-point dose response titrations of compounds in 60 nL DMSO (0.3% f.c. DMSO (v/v)). Mixtures were incubated for 3 hours and read in an EnVision plate reader (Perkin Elmer) with Ex/Em 615/665. To determine the potency (EC50) and extent of NCOR1 recruitment, TR-FRET ratios were normalized to the average ratio of DMSO control wells (0%) and to the average maximum ratio for positive control compound (T0070907 (2-chloro-5-nitro-N-4-pyridinyl-benzamide); defined as 100%) in CDD Vault and analyzed using the Levenberg-Marquardt algorithm.
Compound potency (IC50) and maximal extent of MED1 repulsion to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylated MED1 LxxLL peptide (Biotin-VSSMAGNTKNHPMLMNLLKDNPAQ-amide) to PPARG/RXRA LBD heterodimer. Specifically, a 20 microliters of TR-FRET master mix consisting of 2 nM WT PPARG LBD (e. coli expressed, His-TEV-Q203-Y477; Uniprot ID P37231-2), 2 nM WT RXRA LBD (e. coli expressed, Flag-TEV-E228-T462; P19793-1), 350 nM NCOR1, 80 nM Rosiglitazone, 175 nM streptavidin-d2 (Cisbio) and 0.3 nM Anti-His Tb(Cisbio) in 25 mM MOPS pH 7.4, 25 mM KCl, 1 mM EDTA, 0.01% BSA, 0.01% Tween-20 and 1 mM TCEP was added to 384-well plates containing duplicate 10-point dose response titrations of compounds in 60 nL DMSO (0.3% DMSO f.c. (v/v)). Mixtures were incubated for 3 hours and read in an EnVision plate reader (Perkin Elmer) with Ex/Em 615/665. To determine the potency (IC50) and extent of MED1 repulsion, TR-FRET ratios were normalized to the average ratio of DMSO control wells (0%) and to the average minimum ratio for positive control compound (GW9662 (2-chloro-5-nitrobenzanilide); defined as 100%) in CDD Vault and analyzed using the Levenberg-Marquardt algorithm.
5637 (PPARG amplified) and HT1197 (RXRA S427F mutation) cells were used for assessment of modulation of PPARG target genes using quantitative PCR. Cells were treated for 24 hours with PPARG inverse agonists prior to analysis of FABP4 (IDT, Cat: Hs.PT 58.20106818) and ANGPTL4 (IDT, Cat: Hs.PT 58.25480012) expression, with expression of the housekeeping gene TBP (IDT, Cat: Hs.PT 58v.39858774) used to normalize expression across samples. Quantitative PCR was performed using an ABI QuantStudio 7 Flex Reaction system. Data were analyzed and reported relative to DMSO control using the comparative Ct method (AACt).
While we have described a number of embodiments, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.
The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference. Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one with ordinary skill in the art.
This application claims the benefit of priority to U.S. Provisional Application No. 63/317,740 filed Mar. 8, 2022, the entire contents of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2023/063643 | 3/3/2023 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63317740 | Mar 2022 | US |
